Markets:

Overview

News

Currencies

International

Treasuries

ADC Therapeutics SA Common Shares (NY:ADCT)

3.990 -0.030 (-0.75%)

Official Closing Price Updated: 7:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about ADC Therapeutics SA Common Shares

< Previous 1 2 3 4 Next >

The 3 Most Undervalued Biotech Stocks to Buy in February 2024 ↗

February 08, 2024

With patience, some of the most undervalued biotech stocks can create massive wealth, such as these three to consider.

Via InvestorPlace

Analyst Expectations for ADC Therapeutics's Future ↗

November 20, 2023

Via Benzinga

Why BEST Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket ↗

November 06, 2023

Gainers Carbon Revolution Public Limited (NASDAQ: CREV) shares surged 358% to $134.37 in pre-market trading after gaining 100% on Friday. The company’s stock began trading on Friday following merger...

Via Benzinga

The Latest Analyst Ratings for ADC Therapeutics ↗

September 12, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2023 ↗

August 10, 2023

Via Benzinga

A Preview Of ADC Therapeutics's Earnings ↗

August 07, 2023

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

July 25, 2023

On Tuesday, 56 companies set new 52-week lows.

Via Benzinga

4 Analysts Have This to Say About ADC Therapeutics ↗

July 25, 2023

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

July 21, 2023

On Friday, 54 companies hit new 52-week lows.

Via Benzinga

Earnings Preview: ADC Therapeutics ↗

February 27, 2023

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

July 24, 2023

On Monday morning, 70 companies achieved new lows for the year.

Via Benzinga

ADC Therapeutics Pulls Plug On Mid-Stage Zynlonta Study In Untreated Lymphoma Patients After Patient Deaths ↗

July 21, 2023

ADC Therapeutics SA (NASDAQ: ADCT) announced that it plans to discontinue the Phase 2 LOTIS-9 trial evaluating Zynlonta (loncastuximab tesirine-lpyl) and rituximab in unfit or frail patients with...

Via Benzinga

Dow Rises More Than 200 Points; Adial Pharmaceuticals Shares Spike Higher ↗

July 11, 2023

U.S. stocks traded higher toward the end of trading, with the Dow Jones surging more than 200 points on Tuesday. The Dow traded up 0.73% to 34,193.60 while the NASDAQ rose 0.25% to 13,720.16. The S&P...

Via Benzinga

The Latest Analyst Ratings for ADC Therapeutics ↗

January 24, 2023

Via Benzinga

4 Analysts Have This to Say About ADC Therapeutics ↗

January 04, 2023

Via Benzinga

Why Siyata Mobile Shares Are Trading Lower By 21%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

July 11, 2023

Gainers CytoMed Therapeutics Limited (NASDAQ: GDTC) shares climbed 129.5% to $8.01 after gaining 9% on Monday.

Via Benzinga

Crude Oil Rises 2%; ADC Therapeutics Shares Plummet ↗

July 11, 2023

U.S. stocks traded higher midway through trading, with the Dow Jones surging over 100 points on Tuesday. The Dow traded up 0.41% to 34,082.47 while the NASDAQ rose 0.29% to 13,725.52. The S&P 500, also...

Via Benzinga

Dow Jumps Over 100 Points; US Small Business Optimism Index Tops Estimates ↗

July 11, 2023

U.S. stocks traded higher this morning, with the Dow Jones gaining over 100 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.40% to 34,080.13 while the NASDAQ rose 0.23% to...

Via Benzinga

ADC Therapeutics Stock Is Plunging Today - What's Going On? ↗

July 11, 2023

ADC Therapeutics SA (NASDAQ: ADCT) has voluntarily paused enrollment of new patients in the Phase 2 LOTIS-9 trial evaluating Zynlonta (loncastuximab tesirine-lpyl) and rituximab (Lonca-R) in unfit or...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 24, 2023 ↗

April 24, 2023

Via Benzinga

Tesla And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

January 13, 2023

U.S. stock futures traded mixed this morning. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

March 21, 2023

On Tuesday, 74 companies achieved new lows for the year.

Via Benzinga

TSMC, CommScope Holding And Other Big Stocks Moving Higher On Thursday ↗

January 12, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 150 points on Thursday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

March 14, 2023

Tuesday's morning session saw 84 companies set new 52-week lows.

Via Benzinga

Nike, FedEx And Some Other Big Stocks Moving Higher In Today's Pre-Market Session ↗

December 21, 2022

U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session.

Via Benzinga

Why KNOT Offshore Partners Shares Are Trading Lower By Around 38%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

January 12, 2023

Gainers BigBear.ai Holdings, Inc. (NYSE: BBAI) shares jumped 239% to $2.8715 after the company announced it has been awarded a multiple award $900 million Indefinite Delivery/Indefinite Quantity...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

December 21, 2022

We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Wednesday

Via InvestorPlace

Why Core Scientific Shares Are Trading Lower By Around 32%; Here Are 26 Stocks Moving Premarket ↗

December 21, 2022

Gainers ADC Therapeutics SA (NASDAQ: ADCT) shares rose 36.8% to $4.35 in pre-market trading. ADC Therapeutics and Sobi announced European Commission approval of ZYNLONTA for the treatment of relapsed...

Via Benzinga

Week In Review: Full-Life Acquires Focus-X And Its Eight Radiotherapeutics In $245 Million Deal ↗

December 04, 2022

Full-Life Technologies, a Brussels-Shanghai radiotherapeutics company, will acquire Focus-X Therapeutics for up to $245 million. Using its proprietary peptide engineering technology, Focus-X has built...

Via Talk Markets

Stocks That Hit 52-Week Lows On Monday ↗

November 28, 2022

On Monday, 79 companies reached new 52-week lows.

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

ADC Therapeutics SA Common Shares (NY:ADCT)

Headline News about ADC Therapeutics SA Common Shares

Starting at $3.75/week.

Subscribe Today